Reduction of Inflammatory and Noninflammatory Lesions with Topical Tyrothricin 0.1% in the Treatment of Mild to Severe Acne Papulopustulosa: A Randomized Controlled Clinical Trial

Abstract

Background/Aims: Antibiotic-induced drug resistance requires new approaches in topical acne treatment. Tyrothricin is known to produce no resistance. In this study, it was tested for the first time in topical acne treatment. The efficacy and tolerability of topical tyrothricin 0.1% was evaluated. Methods: Arandomized, active comparator-controlled, exploratory, observer-blind clinical study was conducted in 24 patients with acne papulopustulosa. Randomization on a split-face was either tyrothricin versus clindamycin + benzoyl peroxide (BPO) (n = 12) or tyrothricin versus BPO 5% (n = 12). The main outcome was change in inflammatory and noninflammatory lesion counts. Results: The mean differences in inflammatory lesion counts from baseline were -12.3 (95% CI: -20.5 to -4.1) in clindamycin + BPO, -10.2 (95% CI: -15.3 to -5.0) in BPO 5%, and -7.7 (95% CI: -11.7 to -3.7) in tyrothricin. Tyrothricin reduced noninflammatory lesions (mean difference: -6.5 (95% CI: -11.6 to -1.4) and caused less product-related adverse events (n = 31) compared to BPO (n = 37) and clindamycin + BPO (n = 20). Conclusion: The results indicate that tyrothricin might be a candidate for treating acne and it seems to be more tolerable than both comparator treatments.

Consensus on Wound Antisepsis: Update 2018

“…Many dermatological patients suffer from different types of erosive skin lesions, e.g., follicular bacterial infections [22,23] or eczema [24]. Often, local antibiotics are used instead of considering antiseptic options for treatment, although according to expert opinion, the latter are more effective and do not pose a risk of resistance development [22].…”

Tratamentos medicamentosos para acne vulgar em adolescentes e jovens adultos

“…Com o intuito de reduzir o surgimento de tais bactérias, uma opção terapêutica que é capaz de estimular a cicatrização de feridas de pele sem induzir resistência bacteriana é a Tirotricina 0,1%, um peptídeo antimicrobiano. Assim, um estudo realizado por Richter et al (2016), comparou a resposta terapêutica entre a tirotricina 0,1%, peróxido de benzoíla (BPO) e uma combinação de clindamicina + BPO. Os resultados do estudos mostraram que a regressão de lesões inflamatórias e não inflamatórias foram mais acentuadas com o uso clindamicina + BPO e BPO, respectivamente.…”

Self-Reported Skin Changes by a Selected Number of Astronauts after Long-Duration Mission on ISS as Part of the Skin B Project

“…To fight acne-prone skin, a special care is needed to remove excess sebum without irritating the skin, and thus good skin care can control mild acne. Another promising approach would be the application of antimicrobial peptides such as tyrothricin in the treatment of mild acne [8]. …”